1. 1-24 of 51 1 2 3 »
    1. NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.

      Read Full Article
    2. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.

      Read Full Article
      Mentions: Treatment COG
    3. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

      Read Full Article
      Mentions: Treatment COG
    4. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    5. Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors

      Phase II

      Biomarker/Laboratory analysis, Treatment

      12 months to 30 years

      AFLACST1502

      NCI-2015-01637, IRB00082488, NCT02574728

      This phase II trial studies how well sirolimus and continuous or frequent treatment with low doses of chemotherapy work in treating younger patients with solid or central nervous system (CNS) tumors that have come back or have not responded to previous treatment.

      Read Full Article
    6. Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

      "The purpose of this research study is to evaluate a new investigational drug to prevent reoccurrence of neuroblastoma that is in remission. This study drug is called DFMO. The objectives of this study will be to monitor for safety and look at efficacy of DFMO.  The safety of the proposed dosing regimen in this trial will be tested by an on-going risk/benefit assessment during the study. A patient benefiting from treatment, not progressing on therapy, and in the absence of any safety issues associated with DFMO may continue on treatment up to 27 cycles with the expectation that there ...

      Read Full Article
      Mentions: Treatment MIBG DFMO
    7. NCI-MATCH trial will link targeted cancer drugs to gene abnormalities

      NCI-MATCH trial will link targeted cancer drugs to gene abnormalities

      Investigators for the nationwide trial, NCI-MATCH: Molecular Analysis for Therapy Choice (EAY131), announced today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago that the precision medicine trial will open to patient enrollment in July. The trial seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of their cancer type.

      Read Full Article
      Mentions: ASCO
    8. Researchers report initial feasibility of identifying patients who are exceptional responders to cancer therapy

      "Since September 2014 the study has reviewed over 80 cases based on clinical information and is collecting tissue for analysis. If a clinician believes their patient qualifies as an exceptional responder, they can submit clinical information about the case, without identifiers, to a dedicated email box. If provisionally accepted, tissue from the tumor is then sent to a central tissue repository which determines if the sample meets the trial criteria and where DNA and RNA is extracted and sent for molecular characterization."

      Read Full Article
      Mentions: Treatment
    9. Lombardi Cancer Center researchers observe when cancer cells stop acting like cancer

      Lombardi Cancer Center researchers observe when cancer cells stop acting like cancer

      "It turns out that high-density cells activated the "Hippo" molecular pathway, an ancient biological mechanism that limits the size of an organ. Low-density cancer cells do not engage Hippo, which means the cells are free to grow unchecked within the organ. The trigger for activating Hippo is a single molecule called YAP."

      Read Full Article
    10. U Penn researchers develop personalized cellular therapy for brain cancer in mice

      U Penn researchers develop personalized cellular therapy for brain cancer in mice

      "The investigational approach begins when some of each patient’s T cells are removed via an apheresis process similar to dialysis, the cells are engineered using a viral vector that programs them to find cancer cells that express EGFRvIII. Then, the patient’s own engineered cells are infused back into their body, where a signaling domain built into the CAR promotes proliferation of these “hunter” T-cells. In contrast to certain T cell therapies that also target some healthy cells, EGFRvIII is believed to be found only on tumor tissue, which the study’s leaders hope will minimize side effects."

      Read Full Article
    11. Hopkins researchers find that a new cancer-fighting strategy would harden cells to prevent metastasis

      Hopkins researchers find that a new cancer-fighting strategy would harden cells to prevent metastasis

      "The research team tested 4-HAP on lab-grown pancreatic cancer cells and found that it affected the myosin in their skeletons in a way that made them harder. "We think that being relatively soft lets invading cancer cells slip through the body and colonize new areas," Surcel says. "You can envision an octopus having a much easier time getting through a small opening than would a lobster. 4-HAP seems to make the cancer cells more like the lobster."

      Read Full Article
      Mentions: Metastasis
    12. Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours

      This is a phase I, dose escalation study where topotecan will be administered at lower doses given more frequently on a prolonged schedule (low dose metronomic; LDM), in combination with a fixed dose of pazopanib. The maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) will be evaluated for LDM topotecan in combination with pazopanib in children with recurrent or refractory solid tumours including CNS tumours. Pharmacokinetic and pharmacodynamic studies will be conducted to further define the exposure to and activity of LDM topotecan in combination with pazopanib.

      Read Full Article
    13. Personalized vaccines could change how we fight cancer

      Personalized vaccines could change how we fight cancer

      "Creating a personalized vaccine begins with samples of DNA from a patient’s tumor and normal tissue. Researchers sequence the DNA to identify mutant cancer genes that make versions of proteins found only in the tumor cells. Then they analyze those proteins to determine which are most likely to be recognized and attacked by T cells. Portions of these proteins are incorporated into a vaccine to be given to a patient."

      Read Full Article
    14. U of Chicago researchers find that STING pathway could be key to tumor immunity

      U of Chicago researchers find that STING pathway could be key to tumor immunity

      "The findings show that when activated, the STING pathway triggers a natural immune response against the tumor. This includes production of chemical signals that help the immune system identify tumor cells and generate specific killer T cells. The research also found that targeted high-dose radiation therapy dials up the activation of this pathway, which promotes immune-mediated tumor control."

      Read Full Article
    15. Dana-Farber researchers take new approach to stop 'most wanted' cancer protein

      Dana-Farber researchers take new approach to stop 'most wanted' cancer protein

      Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells – employing a strategy that turns the protein’s own molecular machinations against it. In a study published online by the journal Cell, the scientists used a specially crafted compound to disrupt the protein’s ability to rev up its own production and that of other proteins involved in tumor cell growth.

      Read Full Article
      Mentions: MYCN
    1-24 of 51 1 2 3 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video